Navigation Links
PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
Date:5/15/2013

Cary, NC (PRWEB) May 15, 2013

PharmaDirections has added another issued patent to their list of patents where they helped invent new technology for their clients. This one is United States Patent 8,318,788 which has been issued for “Layered Pharmaceutical Formulations”. This was a second patent that was a result of a collaborative formulation development effort between the scientists at Orexigen, PharmaDirections and their sub-contractors.

The technology is for multiple layered pharmaceutical formulations for drug products such as Contrave®, a treatment for obesity. The patent is assigned to Orexigen Therapeutics, Inc. who currently has an NDA for Contrave® under review at the FDA. In the example of an oral, controlled release dosage formulation, the middle layer is inert and dissolves in vivo to leave two separated drug containing layers intact until dissolution begins. This was done to separate potentially interacting layers from one another within the tablet and to allow each pharmaceutical layer to have its own controlled release dissolution profile. The pharmacokinetic modeling and formulation design was done at PharmaDirections.

"Our collaborative effort with Orexigen resulted in multiple accomplishments including this issued patent and the submission of 4 other patent submissions,” said Dr. Richard Soltero, President of PharmaDirections. “This brings us to 21 issued and issued patents for our clients where a PharmaDirections staff member was one of the inventors. We have helped a lot pharmaceutical companies find additional intellectual property by solving problems of bioavailability, stability or off-label competition.”

During the period from 2005 to 2008, PharmaDirections developed and manufactured several products for Orexigen including Contrave® and Empatic™. This relationship was published in Orexigen’s S-1statement issued in 2005 where it noted: “PharmaDirections is our primary drug development consultant and manages subcontractors on our behalf.”

About PharmaDirections:

PharmaDirections is a pharmaceutical project management and consulting group focused on CMC (Chemistry, Manufacturing and Controls), formulation development, preclinical and regulatory affairs. They utilize a mix of technical expertise, software and proprietary tools, such as GastroPlus™, when inventing new intellectual property for clients or developing formulations that solve difficult problems.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10720248.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
2. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
3. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
4. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
5. The Second Rarest Job in America: Atlanta Dentist Discusses New Bureau of Labor Statistics that Reveal Low Number of Prosthodontists
6. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
7. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
8. Rust Remover That Clears Rust in Seconds Revealed by My Cleaning Products, Company Gives Out Samples of Product to Affirm Effectiveness
9. Genuine Bio Fuel Inc.’s Second Chance Program Proves to Be a Model for Successful Hiring in the Biodiesel Industry
10. Amgen Announces 2013 Second Quarter Dividend
11. Organic-Based Bed Bug Spray Kills Bed Bugs in Seconds, My Cleaning Products Releases Samples of the Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):